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ecause schizophrenia is a progressively deterio-
rating disease that irreversibly affects quality of life,life
expectancy itself,as well as cognitive,social,and voca-
tional performance,attempts to detect it and treat it as
early as possible are obvious goals of therapy.The impor-
tance of early detection and treatment is underscored by
the fact that the onset and aggravation of psychosis occur
in late adolescence and early adulthood, a time when
many life-long vocational and social milestones are
determined.Hence,it is reasonable to assume that any
action that postpones the onset or aggravation of active
psychosis will have long-term benefits.
The notion of early treatment of psychosis and schizo-
phrenia was brought to the forefront of clinical research
by an article by Wyatt,
1 who, after comparing the out-
come of patients whose illness started before and after
the availability of antipsychotic drugs,concluded that the
latter had a better long-term outcome.Coupled with the
observation that,in the years before psychosis and schiz-
ophrenia fully manifest,other less severe and less puta-
tive manifestations emerge, this raised the hope that
these earlier manifestations could be used to diagnose
impending illness and possibly prevent it or ameliorate
its prognosis. Furthermore, as clues about the patho-
physiology of schizophrenia are emerging,such as genes
of predisposition,it becomes reasonable to hypothesize
that,if these clues translate into reliable biological mark-
ers,they will assist early detection and,moreover,earlier
treatment. Similarly, identification of environmental
effects increasing (or decreasing) the risk for schizo-
phrenia raised the hope that these risk factors could be
manipulated toward primary or secondary prevention.
Moreover,the observation that,even after the first psy-
chotic episode has occurred,persistent pharmacological
treatment can produce lengthy psychosis-free periods in
most patients led investigators and clinicians to view the
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To achieve the best therapeutic results in schizophrenia—
like most other disorders—primary prevention is prefer-
able to early and prompt treatment, which, in turn, is
preferable to treatment of chronically established illness.
Unfortunately, there currently exist no accurate markers
that can provide information regarding the future course
of illness and guide treatment in asymptomatic or mildly
symptomatic individuals. Therefore, most treatment
efforts are currently focused on patients who have already
experienced their first psychotic episode. This paper
reviews the efforts to identify accurate markers heralding
psychotic illness, as well as treatment considerations in the
early phase of the disease.  
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(e-mail: davidso@netvision.net.il)early phase of the illness as a “window of therapeutic
opportunity.”
2 Supporting the view that early and persis-
tent treatment has long-term benefits is a study demon-
strating that the functional outcome after 15 years of fol-
low-up is affected (negatively) by the cumulative time of
active psychosis during the first 2 years of illness.
3
For all these reasons,the last two decades have witnessed
a proliferation of treatment structures focusing on the
period surrounding the first episode of psychosis.Some
of these structures are operating as clinics within the tra-
ditional medical/psychiatric establishment, some from
youth centers and even malls,and others in the form of
hotlines and Internet sites.All these efforts are aimed to
detect future psychotic individuals as early as possible,
bring them to treatment,and keep them in treatment.
4
Furthermore, a longstanding biannual international
meeting (International Conference on Early Psychosis),
hundreds of individual articles in peer-reviewed journals,
special journal issues devoted entirely to the subject of
premorbid and recent-onset psychosis, a plethora of
books, as well as specific guidelines to treat early psy-
chosis all serve as evidence of the importance clinicians
and investigators assign to the very early phases of psy-
chotic illness.Following the trend in academic psychia-
try,in their quest to provide the most cost-effective care,
governments and health care providers are investing in
research and practice of early detection and persistent
treatment of the early phases of psychosis.Government-
funded research networks have proliferated in the USA,
Germany,Norway,Australia,UK,and Canada,to name
but a few.
An overview of the research and treatment activities
associated with the premorbid and recent-onset psy-
chosis reveals the acquisition of novel, valuable knowl-
edge—and some disappointments.The valuable knowl-
edge has been concentrated in identifying genes that
may predispose an apparently healthy individual to dis-
crete, putative manifestations related to schizophrenia
(ie, endophenotypes). Putative manifestations, such as
poor attention
5 and other cognitive deficits,
6 are present
in patients and their non-ill first-degree relatives more
often than in the general population. Investigating the
endophenotypes related to schizophrenia is valuable in
terms of both understanding the illness and developing
markers that are likely to be present even in the absence
of full-blown manifestation of illness.Furthermore,accu-
mulating evidence indicates that environmental factors
affect the likelihood of presenting schizophrenia
7 and
that at least some of the risk factors can be modified and
reduced.
8 Progress has also been made in understanding
the characteristic response to treatment
9 of individuals
recently affected by psychosis and improving their treat-
ment.
The disappointments, on the other hand, consist mostly
of the inability to utilize the early manifestations (behav-
ioral, cognitive, and emotional deficits) as reliable, clin-
ically useful markers predicting psychosis and schizo-
phrenia and apply them toward secondary or primary
prevention.This is because the subtle cognitive devia-
tions from established norms and the occasional social
withdrawal,
10 depressed mood, or apparently odd and
even pathological behavior
11 that have been suggested
as markers for future schizophrenic illness are all too
common in the general population of adolescents and
young adults.Also, schizophrenia as a fully manifested
syndrome with the characteristic downhill course is a
rare disease in the general population (<1%).Therefore,
it is difficult to diagnose a rare disease based on behav-
iors, emotions, and performances (mostly cognitive) 
that are very common in the general population.
12
Consequently,effective treatment of individuals before
they manifest psychosis, without unnecessarily treating
those who will never manifest it, will remain an elusive
goal until we can identify valid biological markers and
environmental risks on the causative pathway to psy-
chosis.
Finding reliable markers heralding 
schizophrenia and applying them 
toward prevention
Despite the undisputable evidence that the degree of
relatedness of an individual to another individual already
affected by schizophrenia increases the risk of manifest-
ing the illness,most individuals diagnosed with the dis-
ease do not have an affected relative.Furthermore,the
concordance among monozygotic twins is <50%.Taken
together, these points indicate a genetic contribution 
to the illness, but rule out the possibility of simple
mendelian inheritance and underscore the environmen-
tal contribution.To explain the mode of inheritance of
this illness,as well as the delayed and very heterogeneous
manifestation,it was hypothesized that multiple suscep-
tibility genes interact with environmental influences.
However, before such a hypothesis can be validated,
major obstacles have to be overcome.
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8The first obstacle is in the realm of identifying multiple
susceptibility genes acting additively or multiplicatively
to affect brain function by modulating neural develop-
ment and neurotransmitters and hence the correspond-
ing brain microcircuits.
13This task is particularly daunt-
ing since each gene probably confers a small risk or
protective effect (no more than threefold) and, at the
same time,could modulate the effects of other suscepti-
bility genes.Hence,it is likely that more than one con-
stellation of genes will act together to produce suscepti-
bility to the same particular behavior,emotion,or pattern
of thinking. Similarly, the same genetic constellation
could have different behavioral manifestations depend-
ing on environmental interactions.Even after genes con-
ferring susceptibility for psychosis have been identified,
it is still essential to determine how the specific gene
product (protein or enzyme) affects neural transmission
and brain circuits,and translate these effects into well-
defined emotions,behaviors,and cognitive functioning
(or phenotype).Despite these obstacles,some biological
markers associated with schizophrenia have been identi-
fied,such as met/val substitution on the catecholamine
O-methyl transferase gene (COMT),which accounts for
a small part of the cognitive impairment among some
schizophrenia patients.More important,however,is the
observation that the malfunction in COMT,an enzyme
affecting dopamine metabolism, can be conceptually
placed on the etiological pathway to the illness, which
gives the finding a biological plausibility.Furthermore,
despite the fact that markers like the COMT abnormal-
ity explain only a negligible fraction of the vulnerability
for schizophrenia,such findings open the way to decom-
pose the schizophrenic syndrome into biological subcat-
egories with corresponding clinical manifestations.Thus,
keeping the prevention paradigm in mind, it could be
plausible to intervene pharmacologically in future
patients and in their nonaffected first-degree relatives
who carry the mutation. Unfortunately, at this stage,
there exists no sufficient biological rationale or adequate
and putative pharmacological tools to conduct large-scale
definitive trials to test these hypotheses.
Second,constellations of genes might at best confer sus-
ceptibility for abnormal emotions,behaviors,and discrete
intellectual deficits,which represent the illness interme-
diate endophenotypes for the illness, but not for diag-
nostic classifications agreed upon by expert committees.
Yet, the designation of an individual as a sufferer of
schizophrenia is still based on a cluster of abnormal
behaviors, emotions, and perceptions, which together
have an impact on social and vocational performances.
Similar,but not identical constellations of susceptibility
genes might determine the manifestation of any combi-
nation of anxiety,depression,and withdrawn behavior.
All such manifestations are not only part and parcel of
schizophrenia or comorbidities,but are also manifesta-
tions of other Diagnostic and Statistical Manual of Mental
Health (DSM) disorders, such as anxiety disorder and
dysthymia.This puts schizophrenia on a continuum with
other mental disorders, and leaves the phenotype for
which early predictive biological markers are investi-
gated uncertain.
It is possible that our current knowledge of brain func-
tioning and malfunctioning parallels the knowledge of
the cardiovascular system functioning and malfunction-
ing several hundred years ago.At that time, it was far
from obvious that a common atherosclerotic etiopatho-
physiology could underlie the occasional palpitations
related to mild myocardial ischemia, the sudden chest
pain related to acute myocardial infarction, the occur-
rence of night dyspnea,and the swollen legs related to
congestive heart failure,all of which affect physical func-
tioning on a continuum of severity.It was also not obvi-
ous how to distinguish between the transient elevation of
glucose blood levels due to the stress of acute myocardial
infarction,which is an epiphenomenal marker of active
illness not etiologically related to the underlying athero-
sclerotic illness,and the persistently abnormal values of
blood glucose level due to diabetes mellitus,which is a
marker of risk etiologically related to the underlying ill-
ness.Moreover,it could not even be conceived that dif-
ferent constellations of genes,such as genes predisposing
to abnormal lipid metabolism,abnormal glucose metab-
olism, and hypertension, could alone or in interaction
increase the risk for the same lesion (the atherosclerotic
lesion),which could be manifested as cognitive impair-
ment (vascular dementia),chest pain,or the inability to
walk or sleep flat.No wonder,therefore,that the classi-
fication and treatment of psychosis,anxiety,and depres-
sion might be revolutionized by a more profound bio-
logical understanding of brain functioning and
malfunctioning.Perhaps then it will be possible to diag-
nose impending psychosis by observing aberrant behav-
ior coupled with a biological marker in an adolescent and
distinguish it from the eccentric behavior that is part of
normative adolescent turmoil.
The third hurdle consists in linking between putative
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9environmental influences,genes,and the onset of schizo-
phrenia symptoms.For example,famine during a specific
period of pregnancy is a putative environmental effect
that has an impact on the genetic vulnerability to schiz-
ophrenia
14 only during a limited time window (critical
period) of development, but has no effect outside this
period.However,periods as long as 10 to 15 years may
elapse between exposure to the environmental influence
and initiation of the disease process (induction period),
or in the case of schizophrenia between initiation of dis-
ease process (ie,prodrome) and the diagnosis of the dis-
ease (latency period).Long periods of time between the
critical,induction,and latency periods make it difficult to
detect the real causal agents,and the strength of associ-
ation between an exposure to the environmental influ-
ence and the disease.Furthermore,some of the risks for
schizophrenia,such as intrauterine stress and birth com-
plications,late age of father at conception,drug abuse,
head trauma,urbanization,immigration,and poor social
status, are common to other diagnostic categories and
behavioral abnormalities than schizophrenia.The diffi-
culties in defining the schizophrenic phenotype further
increase the difficulties in associating between the risk
and the illness.Again using the cardiovascular paradigm
projected several hundred years ago,it would have been
difficult to link smoking and plenty of food,both symbols
or prosperity and happiness, to disease. It would have
been even more difficult to take the next step and
hypothesize that predisposition to smoke
15 or eat exces-
sively
16 are affected by individual genetic makeup and
that the end result (the metabolic syndrome,the athero-
sclerotic lesions,and the consequent cardiovascular mal-
function) reflects the interactions between genes and
environment.
17 Hopefully, in the foreseeable future,
apparently puzzling findings, such as the synergism
between family history and living in an urban area
increasing the risk for schizophrenia,
18 will be unraveled.
Fourth,despite the broad agreement among schizophre-
nia researchers that premorbid and prodromal manifesta-
tions exist,the characteristics and prevalence of the man-
ifestations are far from well elucidated.To fully elucidate
the premorbid and prodromal manifestations and their
respective prevalence,it is necessary to follow a randomly
sampled birth cohort throughout the entire age of risk for
schizophrenia.A related,but less informative,strategy is
to follow apparently healthy individuals hypothesized to
be at high risk for schizophrenia,such as first-degree rela-
tives of affected individuals. Unfortunately, the birth
cohort strategy is impractical because schizophrenia has a
very low incidence and the age of risk spans more than
four decades of life and appears to be different for males
and females.Thus,following a birth cohort of 10 000 indi-
viduals for 40 years,starting at age 5 would detect approx-
imately 90 cases of schizophrenia (not accounting for attri-
tion), which is insufficient to make any statement
regarding the premorbid and prodromal manifestations,
considering the apparent low prevalence and heterogene-
ity.Also,the high-risk strategy is limited in scope since it
excludes the overwhelming majority of future schizo-
phrenics,who do not have affected first-degree relatives.
Therefore,the most practical designs to learn about the
premorbid and prodromal phenomena have been the tak-
ing of the personal and psychiatric history upon the diag-
nosis of psychosis or schizophrenia.However,this strategy
is dependent on the availability of a good,objective infor-
mant and is vulnerable to recall biases.Occasionally,it has
been possible to access detailed psychometric aptitude
tests and scholastic records of schizophrenic patients col-
lected many years before the illness was manifested and
diagnosed or even suspected (the prospective historical
design).However,since the information was not collected
with the goal of elucidating the premorbid or prodromal
characteristics of schizophrenia,it often lacks the putative
details, which would be helpful to understand the path
from premorbid manifestation to full-blown acute psy-
chosis.Therefore,it is not very likely that in the foresee-
able future it will be possible to map the trajectory lead-
ing from an apparently normal or only slightly deviant
childhood to severe mental illness.
Fifth,the unavailability of reliable markers of impending
illness vis-à-vis the stigma associated with the illness
19 and
the impact that being “at risk” could have on the indi-
vidual raise major ethical dilemmas for those who pro-
pose treatment of individuals who have not yet mani-
fested psychotic symptoms.
Sixth, even if the ethical dilemmas could be resolved,
there is still insufficient data proving that current phar-
macological and/or nonpharmacological interventions are
effective in preventing or delaying the transition from the
prodromal stage to the active stage of the disease.
20
In summary,until a better understanding of brain func-
tioning and the biological pathway leading to severe
mental illness and psychosis are achieved through a com-
bination of basic research and translational research,it is
reasonable to focus on improving the treatment of those
who already manifest psychosis.
State of the art
10The characteristics and treatment of 
the first episode of psychosis
The notion that patients have different treatment needs
and treatment responses during the first 1 to 3 years fol-
lowing the onset of psychosis and schizophrenia com-
pared with the needs and response to treatment during
the rest of the illness, has been raised and researched
since the 1980s.
21 During the first few years of illness,
patients have a more active illness with a course charac-
terized by sharper distinctions between remissions and
exacerbations.Many,but not all,patients have a down-
hill trend, which plateaus later on.
22 However, before
embarking on comparisons between more and less
recent-onset psychosis patients,and before hypothesiz-
ing what can account for these differences,two caveats
should be considered:one related to the definition of the
terms and the other to the patient population.
Recent-onset psychosis and first-episode psychosis are
not DSM diagnostic terms, but terms of convenience
often used as a criterion for intervention trials or to define
patients enrolled in follow-up studies.Recent-onset psy-
chosis often defines individuals who received a diagnosis
of psychosis within the last year,
23 but other authors have
used the term for individuals who have received the diag-
nosis within the last 3 years.
24 Regardless of the term used,
or the definition of the term,it is difficult to determine the
actual onset of psychosis.
25 Determining when the episode
started, or even if this is the first episode, is based on
memory of the patient or the individual providing collat-
eral information.Unfortunately,the recall is often incom-
plete or biased.
26The patient may not be aware that the
perceptions and thoughts experienced before the diag-
nosis were manifestations of psychosis and/or might not
have shared these experiences with the individual pro-
viding collateral information.Access to mental health ser-
vices, the choice of the social environment to refer to
treatment or to tolerate and contain the patient,and the
severity of the illness,
27 all contribute to the gap between
onset,diagnosis,and treatment of psychosis.
The patient population referred to with the terms recent-
onset and first-episode psychosis is generally an adoles-
cent population, since late adolescence is the time of
peak incidence for psychosis and schizophrenia.
Therefore,any conceptualization of recent-onset or first-
episode psychosis must take into consideration the char-
acteristics,needs,and often peculiarities of this age.For
example,it is useless to focus on the lack of insight into
the illness and the poor cooperation with treatment,with-
out considering the rebelliousness,inexperience,and sen-
sation-seeking behavior characteristic of this age.
With all these caveats in mind, a few characteristics of
recent-onset psychosis patients and their response to
treatment are apparent and distinguish them from more
chronic patients:
• Significant improvement in psychotic symptoms occurs
in the majority of patients.
• Inadequate improvement in negative symptoms and
cognitive deficits.
• Enhanced sensitivity to extrapyramidal symptoms
(EPSs).
• Doses of antipsychotics at the lower end of the thera-
peutic range are sufficient to achieve improvement in
psychotic symptoms.
• Rapid,significant,and persistent weight gain occurs.
• Presence of comorbid symptoms,such as postpsychotic
depression,suicide attempts,and violent outbursts.
• Frequent use of alcohol and cannabis.
• Lack of insight into the illness and,consequently,poor
adherence to treatment.
Improvement in psychotic symptoms 
Almost regardless of the antipsychotic drug employed,
clinically significant improvement in psychotic symptoms
occurs in about 80% of the recent-onset psychosis
patients,which is a considerably higher proportion than
the response reported for the most chronic patients.The
worse response of the chronic patients may be due to an
apparent desensitization of the biological mechanism
mediating treatment response as the disease progresses,
but it could also reflect the loss to follow-up of these few
individuals who have a brief episode of psychosis and
never relapse.
28
The variance in response between trials ranges between
30% and almost 100%.This is probably due to the crite-
ria used to define response and to the length of treat-
ment, but not due to a preferential response to one
antipsychotic versus another.The recommendation of
two panels of experts
29,30 and a semi-regulatory body
31 to
use second-generation antipsychotics (SGA) in this pop-
ulation is not based on the superior efficacy of these
drugs,but on their better tolerability.Well-controlled tri-
als comparing haloperidol with olanzapine
32 or risperi-
done
23 failed to show any clear advantage of the SGA to
suppress or ameliorate acute psychosis.
Treatment of the early stages of schizophrenia - Davidson et al Dialogues in Clinical Neuroscience - Vol 7 . No.1 . 2005
11There have been some suggestions that first-episode psy-
chosis patients might need up to 3 months to show full
response to treatment
33,34;however,this notion was not sup-
ported by recent meta-analysis indicating that response to
treatment is much more rapid.
35 It is conceivable that
rather than a biologically driven delay in the antipsychotic
effect,the apparent delay in response to treatment might
reflect non–drug-related factors.The confusion and bewil-
derment associated with the first episode of psychosis and
the first hospitalization,and the difficulties experienced by
the patient and family to accept and adjust to the new cir-
cumstances of a chronic illness that affects most areas of
life might delay recovery and hospital discharge.
There exist no firm guidelines on the treatment of the
minority of patients who,despite treatment with antipsy-
chotic drugs, do not experience remission of psychotic
symptoms or at least significant amelioration.Raising the
initial dose,switching between antipsychotics (typical and
atypical),and combining two antipsychotics are among the
pharmacological interventions frequently employed to
treat refractory patients.However,this pervasive practice,
which is anchored in clinical observations,is not supported
by scientific evidence.Clozapine,the only antipsychotic
shown to present some advantages over the rest of the
antipsychotics in chronically ill, treatment-refractory
patients,appears to be also effective and well tolerated in
drug-naive recent-onset psychosis patients.
36Whether this
is sufficient evidence to infer that clozapine is more effec-
tive than the rest of the drugs in recent-onset patients who
remain psychotic despite initial treatment remains an open
question. Another question not yet addressed by con-
trolled trials is how early should a recent-onset psychosis
patient who does not respond to the antipsychotic drugs
be switched to clozapine.On the one hand,if,as suggested,
a longer duration of untreated psychosis has long-term
detrimental effects
37 and if most other antipsychotics are
not effective in treatment-refractory psychosis,
38 then the
switch should occur as soon as it becomes apparent that
the individual patient might not respond to the initial drug.
Accumulating data indicate that lack of response during
the first 1 to 3 weeks of treatment is predictive of lack of
response during the subsequent weeks.
35,39,40 On the other
hand,because of the rare and manageable,but potentially
lethal, clozapine-induced agranulocytosis, most recent-
onset psychosis patients in daily clinical practice are
treated with several antipsychotic drugs before they are
switched to clozapine.Whether this clinical practice is also
the optimal one remains to be seen.
Negative symptoms and cognitive deficits
In contrast to the remission or at least marked ameliora-
tion of the psychotic symptoms,most patients show inad-
equate improvement in negative symptoms
23,24,32,33 and
cognitive deficits.
41 Even when negative symptoms and
cognitive deficits are improved by antipsychotic drugs,
the benefit is limited to a 0.2 to 0.3 effect size.This is not
surprising considering the process of drug development
in schizophrenia and the nature of negative symptoms
and cognitive deficits.In the absence of a good concep-
tual model for schizophrenia, since the serendipitous
observation that chlorpromazine ameliorates psychosis,
all subsequent drugs have been screened in vitro and in
animal models on the basis of their similarities to chlor-
promazine or to other drugs already proven to amelio-
rate psychosis.To reach the market, drugs had only to
prove that they ameliorate psychotic symptoms in clini-
cal trials,and not negative symptoms or cognitive deficits.
Therefore, currently available agents have not been
designed or selected to affect the two later manifestations
of schizophrenia, negative symptoms and cognitive
deficit.It also appears that the cognitive deficits and,pos-
sibly,negative symptoms are not of recent onset,but are
long-standing, core features of the schizophrenic dis-
ease
6,10 and that cognitive impairment is inherited inde-
pendently of psychosis.
42
EPSs and therapeutic dose range
In addition to the fact that antipsychotic drugs benefit
some but not other aspects of psychosis, many recent-
onset psychosis patients show enhanced sensitivity to
EPSs even at doses of antipsychotic that are within
accepted therapeutic ranges.
43The enhanced sensitivity
to antipsychotic-induced EPSs appears to be true for
both typical
44 and atypical drugs.
34
Doses of antipsychotic at the lower end of the therapeu-
tic range are sufficient to achieve improvement in psy-
chotic symptoms in recent-onset psychosis and are as
effective as doses in the middle and high therapeutic
range.This finding holds for typical
45 as well as for atypi-
cal
23 drugs.In fact,in a posthoc analysis,
23 it was demon-
strated that many recent-onset patients experience ther-
apeutic benefits with 2 to 4 mg haloperidol or risperidone,
after which the benefits plateau, but not the EPSs.
Interestingly, even at low doses, haloperidol produces
more EPSs than olanzapine
32 or risperidone.
23
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It is not clear at the present why patients who have been
ill for several years or several decades need higher doses
of antipsychotic drugs to reach therapeutic benefit and
why they are less sensitive to EPSs.Biological and/or psy-
chological tolerance to EPSs and to therapeutic benefit
could be invoked to explain this phenomenon.For exam-
ple, dopamine supersensitivity might have developed
after many years of dopamine blockade
46 explaining why
higher doses might be necessary.Alternatively,as the dis-
ease continues and remission and improvements become
more elusive,patients,their families,and in particular the
treating staff become increasingly frustrated and tend to
raise the antipsychotic dose and discount the adverse
effects.This is paradoxical considering the fact that most
adverse effects are dose-dependent and that the only fac-
tor that predicts if a patient will remain in treatment at
the end of the first year of illness is the dose of antipsy-
chotic drug.
47
Weight gain
Another adverse effect that affects young recent-onset
psychosis patients is rapid, significant, and persistent
weight gain.
24,32,48,49Young patients treated with some but
not all atypical drugs tend to gain approximately 5 kg
over 2 to 3 months,
32,50 which is mostly abdominally
deposited adipose tissue.Fasting insulin,C-peptide,and
triglyceride levels significantly increase,suggesting the
possible development of insulin resistance.
50 It is con-
ceivable that the mechanism involved in weight gain is
age-dependent,since elderly schizophrenic patients do
not gain weight,
51 but it is also possible that elderly indi-
viduals have already suffered most of the antipsychotic-
induced weight gain and/or that the weight gain is coun-
terbalanced by an aging-dependent weight loss.
Comorbid psychiatric symptoms
Whether the presence of comorbid symptoms, such as
depression,suicide attempts,and violent outbursts,are
more frequent during the first few years following the
first psychotic episode than during the later years is an
unsettled area of research. Similarly, the treatment of
comorbid symptoms and behaviors remains a challenge.
Attempts to understand depression in recent-onset psy-
chosis patients
52 and to treat it
53 have encountered con-
ceptual and practical difficulties.It is not obvious whether
the depressive symptoms are a core feature of the psy-
chotic illness or a reactive response to a severe and debil-
itating illness.Also depressive symptoms tend to overlap
with negative symptoms,
54 neither of which has a good
response to treatment.
55,56
The period around the onset of the first psychotic
episode is also a period when patients are particularly
vulnerable to self-injurious behavior and suicide.
44As for
depression, it is not clear whether such behavior is a
direct result of active psychosis (eg,command hallucina-
tions) that the patient has not yet learnt to ignore,or a
result of demoralization due to a chronic debilitating ill-
ness.
57While the ability to predict and prevent suicide is
limited,treatment with clozapine
58 or risperidone
23 has
been suggested to reduce suicide risk.
Similarly, outbursts of violence have been reported to
occur in first-episode patients and are often treated with
anticonvulsant medication. However, distinguishing
between illness comorbidities and non–illness-related
maladaptive behaviors in young adolescents is not always
feasible.Exaggerated expression of normal frustration
with hurdles of daily life is often viewed and treated as
illness-related aggression. Most importantly, a recent
analysis of the violent outburst in recent-onset psychosis
patients reveals that the majority of the incidents are lim-
ited to verbal violence.
59 This, coupled with a recent
review indicating that anticonvulsant drugs are not help-
ful in treating comorbid symptoms of schizophrenia,
60
should incite us to reconsider the clinical practice of med-
icating poor impulse control and violence in schizo-
phrenic patients with antiepileptic drugs.
Alcohol and cannabis use
Poor impulse control,suicidal attempts,and violence in
recent-onset psychotic patients have also been associated
with frequent use of alcohol and cannabis.
61The use of
alcohol and mostly cannabis was found to be prevalent
in recent-onset psychosis patients.
62 Data suggest that
increased use of cannabis in this group of patients is not
coincidental.One possible explanation is that patients
use alcohol and cannabis as a method of self-medication
and reduction of the social maladjustment associated
with impending psychosis.However,many patients began
to use cannabis many years before the symptoms of the
illness manifest.
63-66 Furthermore,during the premorbid
and prodromal phases,there is no relationship between
the use of cannabis and premorbid social maladjust-
ment.
67An alternative explanation is that the premorbiduse of cannabis is on the etiological pathway to the ill-
ness,and that use of cannabis might interact with other
risk factors contributing to the manifestations or aggra-
vation of psychosis in vulnerable individuals.Support for
this idea is drawn from a report that the density of
cannabinoid receptors was increased in the dorsolateral
prefrontal cortex in subjects with schizophrenia, com-
pared with controls.
68 Regardless of the explanation,the
increased use of illicit drugs in this population detrimen-
tally affects the long-term outcome
69 and therefore con-
stitutes an important target for treatment.Clozapine has
been suggested to be effective in schizophrenia with
comorbid drug abuse,
70 but this suggestion is based on a
single small trial.
Poor adherence to treatment
Despite the obvious need for treatment of psychosis itself
and the comorbid conditions,the treatment of recent-onset
psychosis patients is a most challenging task.Substance
abuse and lack of insight into the illness,and consequently
poor adherence to treatment,are the most often quoted
reasons for this difficulty.
71 Unfortunately,it appears that
poor insight is more common and severe in recent-onset
psychosis patients who have the most severe and perva-
sive form of illness in terms of general psychopathology,
positive and negative symptoms, as well as cognitive
domains.
72This in turn underscores the challenge of treat-
ing the less insightful patients;they are the ones who need
treatment most and are also the least likely to accept it.
While many of the first-episode patients with poor insight
are admitted and occasionally treated involuntarily,
73 for
the long-term maintenance treatment,the patient’s active
cooperation is essential.It is a particularly difficult chal-
lenge to convince patients who have remitted from their
first episode of psychosis and who are not yet familiar
with the cycling nature of the disease that, despite
absence of active psychotic symptoms,they can benefit
from maintenance treatment.
74 Long-term studies indi-
cate that,if not maintained on antipsychotic medication,
more than 50% of the patients who remitted from the
first episode of psychosis will exacerbate during the first
year following remission
75 and the percentage will rise
during the subsequent years.
Although most practicing psychiatrists and guidelines
will recommend that a remitted patient who had a single
episode of psychosis should be treated for at least 1 year,
there are a number of unanswered questions that reflect
the limitations of the current clinical knowledge:
• Is there a preferred maintenance strategy or drug? 
• Can we identify the 50% of the patients who despite
lack of maintenance treatment,will not exacerbate dur-
ing the first year? 
• Can we identify the patients who will exacerbate
despite maintenance treatment? 
• Considering that there are no satisfactory answers for
the last two questions and considering the drugs’
adverse effects,how does pharmacological treatment
impact on the quality of life? 
Most guidelines recommend for maintenance atypical
rather than typical
31 antipsychotics in this population.This
recommendation is supported by a recent trial compar-
ing low-dose haloperidol with low-dose risperidone in
recent-onset psychosis patients,which demonstrated in a
posthoc analysis that,once remitted,more patients ran-
domized to risperidone maintained remission for longer
periods of time than with haloperidol.
23 It is not clear at
this time if this is a class effect or if it is limited to risperi-
done. A very large pan-European maintenance trail
(European First Episode of Schizophrenia Treatment
study [EUFEST]) comparing five of the most prescribed
antipsychotics in first-episode psychosis is currently
underway; hopefully, EUFEST will report definitive
results in 2006 to answer this question.A related ques-
tion is how early should depot injectable antipsychotics
be considered.It is common practice that depot medica-
tions are reserved for the more chronic patient who after
years of treatment have either failed on other drugs or
showed persistent lack of adherence to treatment.
However,in order to best take advantage of the “window
of therapeutic opportunity”
2 presented by recent-onset
patients, this practice should be reconsidered.
Paradoxically,recent-onset patients appear to be the least
adherent,but they are also the most responsive to treat-
ment,and hence have the most to gain from treatment
and probably most to lose from lack of treatment.
Despite some attempts,
76,77 there are no accurate and clin-
ically applicable markers to predict who will remain in
remission despite lack of treatment and who will exacer-
bate despite treatment.Therefore,physicians,patients,
and their families will have to make treatment decisions
in an environment of uncertainty,well aware that some
individuals will unnecessarily suffer drug-induced
adverse effects. ❏
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El tratamiento de la esquizofrenia: desde las
manifestaciones premórbidas al primer epi-
sodio psicótico
Para conseguir los mejores resultados terapéuticos en
la esquizofrenia –como en la mayor parte de los otros
trastornos– la prevención primaria es preferible a un
tratamiento precoz e inmediato, y éste a su vez es
preferible a un tratamiento de la enfermedad que se
ha establecido crónicamente. Desafortunadamente,
en la actualidad no existen marcadores precisos que
puedan aportar información en relación con el curso
futuro de la enfermedad y orientar el tratamiento de
sujetos asintomáticos o con síntomas leves. Por lo
tanto, la mayoría de los esfuerzos terapéuticos actua-
les están enfocados hacia los pacientes que ya han
experimentado su primer episodio psicótico. Este artí-
culo revisa los esfuerzos para identificar marcadores
precisos que sean precursores de una enfermedad psi-
cótica, así como también las consideraciones tera-
péuticas en la fase precoz de la enfermedad. 
Traitement de la schizophrénie : 
des manifestations prémorbides au 
premier épisode de psychose
Pour obtenir les meilleurs résultats thérapeutiques
dans la schizophrénie – comme dans la plupart des
autres pathologies – la prévention primaire est pré-
férable à un traitement rapide et précoce, qui à son
tour, est  préférable au traitement d’une maladie
chronique installée. Malheureusement, il n’existe
actuellement aucun marqueur exact pouvant ren-
seigner sur l’évolution future de la maladie et guider
le traitement chez les sujets ayant peu de symptômes
ou asymptomatiques. Par conséquent, la plupart des
tentatives de traitement se focalisent actuellement
sur des patients qui ont déjà vécu leur premier épi-
sode psychotique. Cet article passe en revue les
efforts d’identification de marqueurs précis annon-
ciateurs d’une maladie psychotique, ainsi que  les
considérations thérapeutiques dans la phase précoce
de la maladie.
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